1
Belleau Bernard, Nguyen Ba Nghe: Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis b.. Iaf Biochem Int, July 8, 1992: EP0494119-A1 (87 worldwide citation)

Use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of hepatitis B is disclosed.


2
Bernard Belleau deceased, Nghe Nguyen Ba: Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B. BioChem Pharma, Leslie A McDonell, Gerald J Flattmann Jr, Fish & Neave, July 2, 1996: US05532246 (21 worldwide citation)

Use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of hepatitis B is disclosed. ##STR1##


3
Pierrette Belleau, Nghe Nguyen Ba: Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B. Shire BioChem, millen White Zelano Branigan P C, July 4, 2006: USRE039155

Use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of hepatitis B is disclosed.


4
Nguyen Ba Nghe, Belleau Bernard Di: Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis b. Biochem Pharma, Belleau Pierette Hf, Nguyen Ba Nghe, MORROW Joy D, July 23, 1992: WO/1992/011852

Use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of hepatitis B is disclosed.


5
Nguyen Ba Nghe, Belleau Bernard: Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis b.. Iaf Biochem Int, October 20, 1993: EP0565549-A1

Use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of hepatitis B is disclosed.